News
PRTA
8.51
-0.82%
-0.07
Weekly Report: what happened at PRTA last week (0914-0918)?
Weekly Report · 16h ago
Weekly Report: what happened at PRTA last week (0907-0911)?
Weekly Report · 09/14 09:59
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Barchart · 09/09 15:05
Weekly Report: what happened at PRTA last week (0831-0904)?
Weekly Report · 09/07 09:54
Weekly Report: what happened at PRTA last week (0824-0828)?
Weekly Report · 08/31 09:59
Weekly Report: what happened at PRTA last week (0817-0821)?
Weekly Report · 08/24 10:00
Major Insider Move Signals Growing Confidence in Prothena Shares
TipRanks · 08/22 02:09
Weekly Report: what happened at PRTA last week (0810-0814)?
Weekly Report · 08/17 10:00
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Prothena (PRTA)
TipRanks · 08/14 16:10
Weekly Report: what happened at PRTA last week (0803-0807)?
Weekly Report · 08/10 09:57
Prothena (PRTA) Stock Shrugs Off Revenue Drop As Pipeline Stakes Rise
Simply Wall St · 08/07 23:41
Piper Sandler Sticks to Its Buy Rating for Prothena (PRTA)
TipRanks · 08/07 15:27
RBC Capital Keeps Their Hold Rating on Prothena (PRTA)
TipRanks · 08/07 11:27
Analyst Reiterates Buy on Prothena, Citing Disciplined Capital Strategy and Undervalued TTR Franchise with Unchanged $30 Price Target
TipRanks · 08/07 10:45
CORRECTION: Prothena Corp Q2 EPS $(0.36) Misses $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate
Benzinga · 08/07 07:42
Form 10-Q – QUARTERLY REPORT"
This is a quarterly report filed by Prothena Corporation Public Limited Company with the United States Securities and Exchange Commission (SEC) for the quarter ended June 30, 2026.
Press release · 08/07 00:11
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 08/05 21:10
Prothena's Collaboration Revenue Could Finally Quiet the Cash Burn Narrative Tomorrow
Barchart · 08/05 16:25
Weekly Report: what happened at PRTA last week (0727-0731)?
Weekly Report · 08/03 09:56
Prothena's Pipeline Credibility Hinges on Whether Milestone Revenue Repeats or Vanishes
Barchart · 07/31 16:08
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.